Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 2;13(2):255.
doi: 10.3390/brainsci13020255.

Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions

Shamima Akter  1 , Mayank Choubey  2 , Mohammad Mohabbulla Mohib  3 , Shahida Arbee  4 , Md Abu Taher Sagor  5 , Mohammad Sarif Mohiuddin  2
Affiliations
Review

Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions

Shamima Akter et al. Brain Sci. .

Abstract

Diabetic polyneuropathy (DPN) is the most frequent, although neglected, complication of long-term diabetes. Nearly 30% of hospitalized and 20% of community-dwelling patients with diabetes suffer from DPN; the incidence rate is approximately 2% annually. To date, there has been no curable therapy for DPN. Under these circumstances, cell therapy may be a vital candidate for the treatment of DPN. The epidemiology, classification, and treatment options for DPN are disclosed in the current review. Cell-based therapies using bone marrow-derived cells, embryonic stem cells, pluripotent stem cells, endothelial progenitor cells, mesenchymal stem cells, or dental pulp stem cells are our primary concern, which may be a useful treatment option to ease or to stop the progression of DPN. The importance of cryotherapies for treating DPN has been observed in several studies. These findings may help for the future researchers to establish more focused, accurate, effective, alternative, and safe therapy to reduce DPN. Cell-based therapy might be a permanent solution in the treatment and management of diabetes-induced neuropathy.

Keywords: cytotherapy; degenerative diseases; diabetic polyneuropathy; stem cell; stem cell therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Factors responsible for diabetic polyneuropathy (DPN).
Figure 2
Figure 2
Effects of stem cell therapy on DPN.
See this image and copyright information in PMC

References

    1. Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9:88. doi: 10.1186/1471-2458-9-88. - DOI - PMC - PubMed
    1. Diabetes-PAHO/WHO|Pan American Health Organization, Bulletin 2022. [(accessed on 16 December 2022)]. Available online: https://www.paho.org/en/topics/diabetes.
    1. Singh A., Choubey M., Bora P., Krishna A. Adiponectin and Chemerin: Contrary Adipokines in Regulating Reproduction and Metabolic Disorders. Reprod. Sci. 2018;25:1462–1473. doi: 10.1177/1933719118770547. - DOI - PubMed
    1. Dai W., Choubey M., Patel S., Singer H.A., Ozcan L. Adipocyte CAMK2 deficiency improves obesity-associated glucose intolerance. Mol. Metab. 2021;53:101300. doi: 10.1016/j.molmet.2021.101300. - DOI - PMC - PubMed
    1. Feldman E.L. Epidemiology and Classification of Diabetic Neuropathy-UpToDate. 2018. [(accessed on 16 December 2022)]. Available online: https://www.uptodate.com/contents/epidemiology-and-classification-of-dia....

LinkOut - more resources